Compare OWLS & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLS | LXRX |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 465.2M |
| IPO Year | N/A | 2000 |
| Metric | OWLS | LXRX |
|---|---|---|
| Price | $6.52 | $1.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.23 |
| AVG Volume (30 Days) | 58.6K | ★ 1.7M |
| Earning Date | 12-29-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,804,100.00 | ★ $70,864,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.29 | ★ 1255.21 |
| 52 Week Low | $6.00 | $0.28 |
| 52 Week High | $90.00 | $1.66 |
| Indicator | OWLS | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 68.63 |
| Support Level | N/A | $1.11 |
| Resistance Level | N/A | $1.23 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 97.86 |
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.